Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent P2-VP8 Subunit Rotavirus Vaccine in Healthy South African Adults, Toddlers and Infants
NCT02646891Phase 2Completed
- Sponsor
- PATH
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trivalent P2-VP8 subunit rotavirus vaccine in rotavirus gastroenteritis (10 arms), sponsored by PATH. Primary endpoints: Number of Participants Experiencing Adverse Events, Number of Participants With Local or Systemic Reactions and 6 more. Started Feb 2016; status: completed.
02
Drugs
trivalent P2-VP8 subunit rotavirus vaccine
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT02646891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646891.